Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening

Oncotarget

Volumn 6, Issue 27, 2015, Pages 24320-24332

  Lee, Jeeyun ^a   Kim, Hee Cheol ^a   Hong, Jung Yong ^b   Wang, Kai ^c   Kim, Sun Young ^a   Jang, Jiryeon ^a   Kim, Seung Tae ^a   Park, Joon Oh ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a   Park, Young Suk ^a   Lee, Jiyun ^a   Lee, Woo Yong ^a   Park, Yoon Ah ^a   Huh, Jung Wook ^a   Yun, Seong Hyeon ^a   Do, In Gu ^a   Kim, Seok Hyung ^a   Balasubramanian, Sohail ^c   Stephens, Philip J ^c   Ross, Jeffrey S ^c,d   Li, Gang Gary ^e   Hornby, Zachary ^e   Ali, Siraj M ^c   Miller, Vincent A ^c   Kim, Kyoung Mee ^a,f   Ou, Sai Hong Ignatius ^g   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c FOUNDATION MEDICINE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e Ignyta   (United States)

^f Samsung Medical Center   (South Korea)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anaplastic lymphoma kinase (ALK) rearrangement; Colorectal carcinoma; Immunohistochemistry; Next generation sequencing

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CETUXIMAB; CRIZOTINIB; ENTRECTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; BENZAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALK GENE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH CARCINOMA; TISSUE MICROARRAY; CHEMISTRY; COLORECTAL TUMOR; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MUTATION; PHOSPHORYLATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SOUTH KOREA; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BENZAMIDES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDAZOLES; MALE; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84943373181     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4462     Document Type: Article

References (25)

1. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371:2167-2177.
2. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 20368:2385-2394.
3. Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, et al. FDA approval summary:crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014;19:e5-11.
4. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009;7:1466-1476.
5. Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, et al. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res. 2014;12:111-118.
6. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382-384.
7. Sullivan HC, Fisher KE, Hoffa AL, Wang J, Saxe D, Siddiqui MT, et al. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer. Appl Immunohistochem Mol Morphol. 2014. [Epub ahead of print].
8. Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer. 2013;119:1627-1635.
9. Lee J, Sohn I, Do IG, Kim KM, Park SH, Park JO, et al. Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS ONE. 9:e90133.
10. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn. 2013; 15:51-61.
11. Choi YL, Lira ME, Hong M, Kim RN, Choi SJ, Song JY, et al. A novel fusion of TPR and ALK in lung adenocarcinoma. J Thorac Oncol. 2014;9:563-566.
12. Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn. 2014; 16:229-243.
13. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-1031.
14. De Braud FG, Pilla L, Niger M, Damian S, Bardazza B, Martinetti A, et al. Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 322014;5. abstr 2502.
15. http.//www.ncbi.nlm.nih.gov/gene/57223, (assessed 1 February, 2015).
16. Yokoyama N, Miller WT. Molecular characterization of WDCP, a novel fusion partner for the anaplastic lymphoma tyrosine kinase ALK. Biomed Rep. 2015;3:9-13.
17. Houang M, Toon CW, Clarkson A, Sioson L, de Silva K, Watson N, et al. ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol. 2014;Jul 2;. [Epub ahead of print].
18. Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 2012;25:1462-1472.
19. Miller J, Peng Z, Wilcox R, Evans M, Ades S, Verschraegen C. Absence of anaplastic lymphoma kinase translocations in signet ring cell carcinomas of the upper gastrointestinal tract. Gastrointest Cancer Res. 2014;7:39-41.
20. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
21. Mano H. Non-solid oncogenes in solid tumors:EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008;99:2349-2355.
22. Grande-García A, Lallous N, Díaz-Tejada C, Ramón-Maiques S. Structure, functional characterization, and evolution of the dihydroorotase domain of human CAD. Structure. 2014;22:185-198.
23. Mano H. ALKoma:a cancer subtype with a shared target. Cancer Discov. 2012;2:495-502.
24. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014; 5:4846.
25. Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013; 24:2589-2593.